Food and Drug Administration awards $10 million contract to team to support vaccine safety program

Dr. Marc Suchard, professor of biostatistics, co-leads team of researchers supporting FDA’s Biologics Effectiveness and Safety (BEST) program.

COVID-19 vaccine

A research team co-led by UCLA Fielding School of Public Health faculty has been awarded a $10 million contract to support the U.S. Food and Drug Administration’s program to ensure vaccines are safe.

“Sound approaches to monitor vaccine safety and effectiveness across large populations have their limitations; this is particularly important with the upcoming roll-out of COVID-19 vaccination programs, and we stand ready to help," said Marc Suchard, UCLA Fielding School of Public Health professor of biostatistics, who will lead methods development under this contract. Some $1.4 million of the grant will go to Suchard’s team at UCLA.

The research team, primarily comprised of faculty from UCLA, Columbia University, and Northeastern University, will provide support to the Food and Drug Administration (FDA)’s Biologics Effectiveness and Safety (BEST) system in its mission to conduct safety and effectiveness surveillance of biologic products (vaccines, blood and blood products, tissues and advanced therapeutics).

The Columbia University Department of Biomedical Informatics serves as the coordinating center for the contractors, operating under the umbrella of the Observational Health Data Services and Informatics (OHDSI) community. OHDSI is a global, multi-stakeholder, interdisciplinary collaborative which aims to bring out the value of health data through large-scale analytics and an open-science approach in order to generate the evidence that promotes better health decisions and better care.

“We are very excited to partner with the FDA to address surveillance of biologics, including vaccine safety, as it brings the knowledge, experience, and tools of OHDSI to bear on problems critically important to the nation,” said George Hripcsak, chair and professor of biomedical informatics at Columbia.

Specific means of FDA support through this grant will include serving in a convening role to 1) develop methods related to using observational data from electronic health records and administrative claims to study the effectiveness and safety of biologics, 2) work collaboratively with FDA staff to plan, develop, coordinate, host and convene meetings and workshops, and 3) educate FDA staff and external stakeholders on the BEST infrastructure, capabilities and applications that serve FDA and stakeholder needs.

“Northeastern is delighted to partner with Columbia and UCLA to support the FDA in this crucial endeavor,” said David Madigan, provost and senior vice president for academic affairs at Northeastern. “OHDSI supports a global community of researchers focused on generating reliable healthcare evidence. This project will greatly accelerate this work.”

The UCLA Fielding School of Public Health, founded in 1961, is dedicated to enhancing the public's health by conducting innovative research, training future leaders and health professionals from diverse backgrounds, translating research into policy and practice, and serving our local communities and the communities of the nation and the world. The school has 631 students from 26 nations engaged in carrying out the vision of building healthy futures in greater Los Angeles, California, the nation and the world.

Faculty Referenced by this Article

Related Content

close-up of virus
November 24, 2020
Research helps identify high-risk populations to aid health officials combating the pandemic

A team of UCLA Fielding School of Public Health researchers has developed a method to better guide public policy related to the control and prevention of COVID-19, based on identifying those most at risk in the pandemic.

Source: Epidemics Volume 33, December 2020 Read Full Article
close-up of virus
October 12, 2020
UCLA Fielding School of Public Health researcher’s work opens doors to understanding COVID-19’s early spread

A UCLA Fielding School of Public Health researcher’s work on two related research projects published in the past month suggests that in both the United States and in Europe, sustained transmission networks of SARS-CoV-2 became established only after separate introductions of the virus that went undetected.

Source: American Association for the Advancement of Science Nature Research Read Full Article